Etodolac XR (Etodolac Extended Release) Patient Information: Side Effects and Drug Images at RxList

Pill Identifier Search

May 27, 2012

Etodolac XR

Ankylosing Spondylitis »

Ankylosing spondylitis facts

Ankylosing spondylitis belongs to a group of arthritis conditions which tend to cause chronic inflammation of the spine (spondyloarthropathies).
Ankylosing spondylitis affects males two to three times more commonly than females.
Ankylosing spondylitis is a cause of back pain in adolescents and young adults.
The tendency to develop ankylosing spondylitis is genetically inherited.
The HLA-B27 gene can be detected in the blood of most patients with ankylosing spondylitis.
Ankylosing spondylitis can also affect the eyes, heart, lungs, and occasionally the kidneys.
The optimal treatment of ankylosing spondylitis involves medications that reduce inflammation or suppress immunity, physical therapy, and exercise.

What is ankylosing spondylitis?

Ankylosing spondylitis is a form of chronic inflammat...

Read the Ankylosing Spondylitis article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Etodolac XR User Reviews >>

Etodolac XR

Rheumatoid Arthritis Slideshow Pictures

Joint-Friendly Exercises Slideshow Pictures

Take the RA Quiz

font size

Etodolac XR
(etodolac) Extended-Release Tablets

Cardiovascular Risk

NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS and Clinical Trials).
Etodolac Extended-Release Tablets, 400 mg, 500 mg and 600 mg is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).

Gastrointestinal Risk

NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS).

DRUG DESCRIPTION

Etodolac Extended-Release Tablets contain etodolac, which is a member of the pyranocarboxylic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains etodolac for oral administration. Etodolac is a racemic mixture of [+]S and [-]R-enantiomers. It is a white crystalline compound, insoluble in water, but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous polyethylene glycol.

The chemical name is (±) 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. The molecular weight is 287.37. Its molecular formula is C₁₇H₂₁NO₃and it has the following structural formula:

Etodolac Extended (NSAIDs) Structural Formula Illustration

The inactive ingredients in etodolac extended-release tablets include: Microcrystalline Cellulose, Povidone, Hydroxypropyl Methylcellulose, Lactose Anhydrous, Magnesium Stearate, HPMC 2910, Polydextrose FCC, PEG 8000, Triacetin, Titanium Dioxide. In addition, the 500 mg and 600 mg tablets contain Indigo Carmine Lake and the 400 mg and 600 mg tablets contain Allura Red AC Lake and Sunset Yellow F.C.F. Lake.

Last reviewed on RxList: 12/9/2008
This monograph has been modified to include the generic and brand name in many instances.